

Trust Headquarters Russells Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-062025-0001671

Date: 2.7.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

I am analysing the treatment of lung cancer and would greatly appreciate it if you could answer the following question:

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 6
- Amivantamab 0
- Atezolizumab Monotherapy 3
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0
- Atezolizumab subcutaneous 0
- Dabrafenib + Trametinib 1
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 3
- Durvalumab 1
- Gemcitabine 0
- Nintedanib + Docetaxel 1
- Nivolumab 0
- Osimertinib 20
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 1
- Paclitaxel 0
- Pembrolizumab Monotherapy 15
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 1
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5
- Pemetrexed + Platinum (Carboplatin/Cisplatin) 9
- RET Inhibitors (Pralsetinib, Selpercatinib) 0
- Sotorasib 1
- Tepotinib 1
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 3
- Other active systemic anti-cancer therapy 18
- Palliative care only unable to run a report for this information
- Amivantamab with carboplatin and pemetrexed **0**
- Cemiplimab with platinum-based chemotherapy **0**

Q2. Does your trust participate in any Clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

Page 1 of 2

FOI/REF FOI-

- No NSCLC trials at present

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ Email: <u>dgft.dpo@nhs.net</u>

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team The Dudley Group NHS Foundation Trust